

7th October, 2025

<p>To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701 (Equity) : 975834 and 976560 (Debt)</p>	<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – EQ</p>
---	--

SUB: PRESS RELEASE REGARDING COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS AG, ANNOUNCED STRATEGIC ALLIANCE WITH CELONIC GROUP TO DELIVER FULLY INTEGRATED ADC DEVELOPMENT AND MANUFACTURING PLATFORM

REF.: DISCLOSURE UNDER REGULATIONS 30 AND 51 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir,

Pursuant to Regulation 30 and 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, today the Company announces that its subsidiary, CARBOGEN AMCIS AG., has Announced Strategic Alliance with Celonic Group to Deliver Fully Integrated ADC Development and Manufacturing Platform.

In this regard, please find enclosed herewith Press Release on the captioned subject.

Kindly take this on your record.

Yours faithfully,
For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary

Encl.: As Above

PRESS RELEASE

DISHMAN CARBOGEN AMCIS LIMITED announces that its subsidiary, CARBOGEN AMCIS AG., has Announced Strategic Alliance with Celonic Group to Deliver Fully Integrated ADC Development and Manufacturing Platform

Ahmedabad, India (07-10-2025) - The Company's subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution with Celonic Group.

CELONIC GROUP, one of the leading "pureplay" Biologics CDMO, and The Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic's advanced biologics capabilities with CARBOGEN AMCIS's expertise in payload synthesis, conjugation, and sterile fill-finish, creating a seamless, end-to-end platform for ADC innovators.

This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and CARBOGEN AMCIS aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.

"This strategic alliance is a direct response to the evolving needs of ADC innovators," said Dr. Samanta Cimitan, CEO of Celonic Group. "By integrating Celonic's advanced biologics platforms with CARBOGEN AMCIS's world-class payload and conjugation capabilities, we're enabling a fully harmonised development and manufacturing pathway, from DNA to drug product. It's a scalable, compliant, and commercially ready solution designed to accelerate innovation and reduce complexity for our partners."

Investing where it matters:

- Celonic Group recently expanded its Biologics Development Center in Basel and GMP manufacturing site in Heidelberg, adding high-yield GS-CHOvolution™ cell line platform, enhanced perfusion-based technologies for process optimization to improve productivity, and commercial-scale biomanufacturing suites.
- CARBOGEN AMCIS delivered its first ADC project in 2005 and has since supported numerous ADC programs across payload, linker, conjugation, and sterile drug product – giving innovators a single accountable partner from early development through market supply. As one of the earliest CDMOs to build dedicated ADC capabilities, CARBOGEN AMCIS has become a go-to partner for linker and payload development and for conjugation with customer-supplied antibodies. The dedicated conjugation suites in Switzerland and clinical-to-commercial and commercial manufacturing of sterile liquid drug-product capability at an ANSM approved, state of the art green field facility in France provide end to end development at supply across all clinical phases

and extensive commercial volume range, with high precision, speed, quality and reliability demanded, across all the programs.

“The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility,” said Stephan Fritschi, CEO of Carbogen Amcis Group. “Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant.”

“For more than 2 decades now we’ve been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies, precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end-to-end ADC path—from cell line to commercial fill-finish—under one coordinated platform,” adds Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group. “Beyond linker and payload excellence, we are deeply evaluating a cutting edge innovative capacity expansion intending continuous-flow conjugation using custom micro-equipment skids. By holding pH, temperature, stoichiometry, and residence time within tight bands.

The integrated offering includes:

- Cell line development and antibody production at scale (Celonic)
- Payload and linker synthesis and at scale manufacturing (CARBOGEN AMCIS)
- ADC conjugation and sterile fill-finish (CARBOGEN AMCIS)
- Regulatory support and CMC documentation for IND, IMPD, and BLA filings

With Celonic upstream and CARBOGEN AMCIS downstream, teams get one accountable partner. This alliance removes variability and removes handoffs so that such life-saving therapies reach families sooner, across the globe.

About Celonic Group

Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO). Celonic’s mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, “next generation” bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic across the two locations.

CARBOGEN AMCIS AG. (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS AG. is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and in India.